Proffered Paper - GU, non prostate 2
700O - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
The abstract concludes: We report for the first time from a prospective trial that Immune high/angiogenesis and stromal low signatures likely predict nivolumab efficacy in m-ccRCC patients.
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
The abstract concludes: With the largest mRCC cohort to date, our study shows ctDNA analysis is feasible and highly concordant with tissue genomic analysis. Exclusive GAs found on both platforms suggests tumor evolution over time and treatment, which may assist in guiding treatment selection in mRCC.
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
The abstract concludes: C + A demonstrated encouraging clinical activity in previously untreated pts with advanced ccRCC with an acceptable safety profile at both C doses evaluated. A phase 3 study of C + A in RCC previously treated with ICI therapy is planned.
LBA25 - Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
The abstract concludes: We demonstrate for the 1st time in m-ccRCC pts that gene expression signatures may enable to enrich response rates. An extensive translational program is planned to identify new biomarkers.
The abstract concludes: Avelumab 1L maintenance + BSC provided OS benefit vs BSC alone across prespecified subgroups of pts whose disease had not progressed with 1L induction CTx and is an important advance for 1L treatment of advanced UC.
See also NEJM ORIGINAL ARTICLE
T. Powles and Others